(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...
Stats | |
---|---|
Dagens volum | 4 839.00 |
Gjennomsnittsvolum | 3 176.00 |
Markedsverdi | 330.62B |
EPS | €0 ( 2024-04-15 ) |
Neste inntjeningsdato | ( €0 ) 2024-07-16 |
Last Dividend | €1.190 ( 2023-08-25 ) |
Next Dividend | €0 ( N/A ) |
P/E | 19.74 |
ATR14 | €0.125 (0.09%) |
Volum Korrelasjon
Johnson & Johnson Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Johnson & Johnson Korrelasjon - Valuta/Råvare
Johnson & Johnson Økonomi
Annual | 2023 |
Omsetning: | €85.16B |
Bruttogevinst: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2023 |
Omsetning: | €85.16B |
Bruttogevinst: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2022 |
Omsetning: | €94.94B |
Bruttogevinst: | €63.85B (67.26 %) |
EPS: | €6.86 |
FY | 2021 |
Omsetning: | €93.78B |
Bruttogevinst: | €63.92B (68.16 %) |
EPS: | €7.93 |
Financial Reports:
No articles found.
Johnson & Johnson Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.190 (N/A) |
€1.190 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.415 | 2008-02-22 |
Last Dividend | €1.190 | 2023-08-25 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 65 | -- |
Total Paid Out | €56.18 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.59 | -- |
Div. Sustainability Score | 3.76 | |
Div.Growth Potential Score | 5.82 | |
Div. Directional Score | 4.79 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RIO1.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
BST.DE | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
JNJ.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
TA1.DE | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% | |
MMM.DE | Ex Dividend Junior | 2023-08-18 | Quarterly | 0 | 0.00% | |
4I1.DE | Ex Dividend Knight | 2023-09-26 | Quarterly | 0 | 0.00% | |
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
OMV.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.453 | 1.500 | 0.949 | 1.424 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.572 | 1.500 | 4.76 | 7.14 | [0.1 - 1] |
payoutRatioTTM | 0.218 | -1.000 | 7.82 | -7.82 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 44.51 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 6.84 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.687 | 1.000 | 1.890 | 1.890 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.54 | 6.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.80 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.572 | 2.50 | 6.63 | 7.14 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 7.89 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.24 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.218 | 1.500 | 7.82 | -7.82 | [0 - 1] |
pegRatioTTM | -0.303 | 1.500 | -5.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.218 | 1.000 | 7.05 | 0 | [0.1 - 0.5] |
Total Score | 5.82 |
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.